The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
CONCLUSION: The improved pharmacodynamic/pharmacokinetic profiles of new long-acting insulin formulations provide greater glycemic control with once-daily dosing. With the growing number of therapeutic choices available, physicians have more scope to individualize patient options for basal insulin therapy.
PMID: 28277867 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Lantus | Levemir | Research